MedTrace Logo

The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Influenza (Acute Upper Respiratory Infection)

NCT02622659 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 468

Last updated 2017-05-22

No results posted yet for this study

Summary

Randomized, double blind, double dummy, positive drug parallel comparison, multi-centre clinical trial to assess the efficacy and safety of Fuganlin Oral Liquid in children with influenza (acute upper respiratory infection).

Conditions

  • Acute Upper Respiratory Infection

Interventions

DRUG

Fuganlin Oral Liquid

less than 1 years old: 5mL each time and three times a day 1\~3 years old: 10mL each time and three times a day 4\~6 years old: 10mL each time and four times a day 7\~12 years old: 10mL each time and five times a day

DRUG

Xiaoer Jiebiao Oral Liquid

1\~2 years old: 5mL each time and twice a day 3\~5 years old: 5mL each time and three times a day 6\~14 years old: 10mL each time and twice a day

Sponsors & Collaborators

  • Guangzhou Yipinhong Pharmaceutical CO.,LTD

    lead INDUSTRY

Principal Investigators

  • Cao xia, MD · Chongqing First People's Hospital

  • Yan yunying, MD · Nanning maternal and Child Health Hospital

  • Hu suping, MD · Nanchang City Hospital of integrated traditional Chinese and Western Medicine

  • Wang leping, MD · Changzhou traditional Chinese medicine hospital

  • Liu Dexing, MD · Liuzhou traditional Chinese medicine hospital

  • Qi Shihe, MD · Xiangyang Central Hospital

  • Ding Lijun, MD · Handan traditional Chinese medicine hospital

  • Yang Liping, MD · Changzhi City People's Hospital

  • Feng Ziwei, MD · Luohe traditional Chinese medicine hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02622659 on ClinicalTrials.gov